All data are taken from published papers. All relevant summary material are in the manuscript itself.

Introduction {#sec005}
============

Syphilis, caused by *Treponema pallidum* subsp. *pallidum*, remains an important sexually transmitted disease worldwide. Some studies suggest the natural history, outcomes of treatment, and likelihood of central nervous system involvement are different in HIV-infected compared to uninfected individuals \[[@pntd.0005880.ref001]--[@pntd.0005880.ref003]\], but consensus has not been reached \[[@pntd.0005880.ref004]\]. Globally the highest rates of syphilis and HIV are in Africa\[[@pntd.0005880.ref005]\]. Based on this and the potential for interaction with HIV in the region, it might be expected that neurosyphilis would be an important and not uncommon manifestation of syphilis in Africa, yet few data are available.

Neurological involvement is one of the most important manifestations of syphilis. Typically neurosyphilis is described as a late manifestation, but neuroinvasion and neurological disease occur in both early and late syphilis\[[@pntd.0005880.ref006]\], and *T*.*pallidum* may be frequently identified in the CSF of patients with early stage syphilis\[[@pntd.0005880.ref007]\]. The clinical spectrum seen ranges from asymptomatic neuroinvasion, meningitis, meningovascular disease presenting as a stroke-like syndrome, and the late stage manifestations of tertiary syphilis: tabes dorsalis and general paresis of the insane\[[@pntd.0005880.ref008]\].

Cerebrospinal fluid (CSF) is frequently abnormal in patients with neurosyphilis with both pleocytosis and raised protein concentration. The Venereal Disease Research Laboratory (VDRL) assay on CSF is normally considered the gold standard for specificity, but is recognised to have limited sensitivity \[[@pntd.0005880.ref009],[@pntd.0005880.ref010]\]. Other CSF tests, including serological assays, such as the Rapid Plasma Reagin (RPR)\[[@pntd.0005880.ref011]\], Fluorescent Treponemal Antibody-adsorption (FTA-ABS)\[[@pntd.0005880.ref012]\] and *Treponema pallidum* haemagglutination assay\[[@pntd.0005880.ref013]\]and molecular assays including PCR\[[@pntd.0005880.ref014]\] have all been assessed for CSF and have variable specificity and sensitivity for the diagnosis of neurosyphilis. Difficulties in interpretation of CSF pleocytosis in individuals co-infected with HIV add to challenges in evaluating the relationship between the two diseases. CSF pleocytosis is seen in individuals with either infection alone \[[@pntd.0005880.ref004],[@pntd.0005880.ref014]\], thus discerning the cause of pleocytosis in co-infected individuals is not possible.

The aim of this study is to review data on neurosyphilis in Africa since the onset of the HIV epidemic.

Methods {#sec006}
=======

Search strategy and selection criteria {#sec007}
--------------------------------------

We searched Pubmed, Medline, EMBASE and the grey literature for references on neurosyphilis in Africa. We searched reference lists of selected papers to identify additional references. We searched for ("CSF" OR "lumbar puncture" OR "meningitis" OR "meningovascular" OR "stroke") AND "syphilis") OR ("neurosyphilis" OR "tabes dorsalis" OR "general paresis") AND (Africa OR each individual country in Africa). We limited the search to studies published between 1^st^ of January 1990 and 15^th^ February 2017 (the date the search was conducted). No language restrictions were placed. We excluded reviews if they did not report new primary material, studies limited purely to comparisons of diagnostic techniques, studies on non-neurological manifestations of syphilis, studies reporting cases occurring before 1990, and studies reporting patients already described in a different paper.

Data extraction {#sec008}
---------------

For each reference we extracted the number of sites in each study, the duration of the study, inclusion and exclusion criteria, diagnostic criteria for neurosyphilis, the clinical syndromes, and the number of HIV infected and uninfected individuals. We also extracted information on the treatment and outcomes of patients in these studies.

Statistical analysis {#sec009}
--------------------

For retrospective and prospective cohorts, we calculated the proportion of study participants who were diagnosed with neurosyphilis according to the individual study criteria. Depending on the study, we assessed the proportion of patients with syphilis found to have neurosyphilis, and the proportion of patients with neurological syndromes who had neurosyphilis. Due to heterogeneity of data no formal pooling of the data or meta-analysis was undertaken.

Results {#sec010}
=======

We identified 189 citations of which 42 met our inclusion criteria ([Fig 1](#pntd.0005880.g001){ref-type="fig"}) (Tables [1](#pntd.0005880.t001){ref-type="table"}--[3](#pntd.0005880.t003){ref-type="table"}).

![Study inclusion flowchart.](pntd.0005880.g001){#pntd.0005880.g001}

10.1371/journal.pntd.0005880.t001

###### Case reports of neurosyphilis---Clinical and diagnostic features.

![](pntd.0005880.t001){#pntd.0005880.t001g}

  Study                                         Country         n   Year   CSF Criteria for Diagnosis of Neurosyphilis   Clinical Syndrome                                                           \% HIV Positive Patients
  --------------------------------------------- --------------- --- ------ --------------------------------------------- --------------------------------------------------------------------------- --------------------------
  Wolf B\[[@pntd.0005880.ref015]\]              Zimbabwe        2   1993   RPR / TPHA                                    One case of early meningitic disease & one case of paranchymatous disease   0%
  Silber E---1998\[[@pntd.0005880.ref016]\]     South Africa    7   1998   VDRL                                          Meningitis                                                                  14% (n = 1)
  Bulundwe KK\[[@pntd.0005880.ref017]\]         South Africa    1   2000   VDRL                                          Meningitis                                                                  100%
  Nunes da Silva MJ\[[@pntd.0005880.ref018]\]   Guinea-Bissau   1   2000   VDRL / TPHA                                   Meningitis                                                                  0%
  Seydi M\[[@pntd.0005880.ref019]\]             Senegal         1   2001   VDRL / TPHA                                   Meningitis                                                                  100%
  Corr P\[[@pntd.0005880.ref020]\]              South Africa    1   2004   VDRL / FTA                                    Meningovascular                                                             100%
  Zouhair K\[[@pntd.0005880.ref021]\]           Morocco         4   2004   Not Stated                                    Tabes Dorsalis                                                              0%
  Harifi G\[[@pntd.0005880.ref022]\]            Morocco         1   2009   TPHA / VDRL                                   Trigeminal Neuralgia                                                        Not Stated
  Salami AK\[[@pntd.0005880.ref023]\]           Nigeria         1   2009   VDRL                                          Meningovascular                                                             100%
  Mrabet D\[[@pntd.0005880.ref024]\]            Tunisia         1   2010   VDRL                                          Tabes Dorsalis                                                              0%
  Kyebambe PS\[[@pntd.0005880.ref025]\]         Uganda          1   2010   VDRL                                          Meningovascular                                                             100%
  Wasserman S\[[@pntd.0005880.ref026]\]         South Africa    1   2011   VDRL                                          Guillan-Barre Syndrome                                                      0%
  Mebrouk Y\[[@pntd.0005880.ref027]\]           Morocco         1   2011   VDRL / TPHA                                   Spinal Meningitis                                                           0%
  Napon C\[[@pntd.0005880.ref028]\]             Burkina Faso    1   2012   VDRL / TPHA                                   Focal Neurology                                                             0%
  Derouich I\[[@pntd.0005880.ref029]\]          Morocco         1   2013   VDRL / TPHA                                   Limbic Encephalitis                                                         0%
  Samia M\[[@pntd.0005880.ref030]\]             Morocco         1   2013   Syphilis serology not otherwise specified     Tabes Dorsalis                                                              0%
  Lakjiri S\[[@pntd.0005880.ref031]\]           Morocco         1   2014   Syphilis serology not otherwise specified     Tabes Dorsalis                                                              0%
  Moolla Y\[[@pntd.0005880.ref032]\]            South Africa    1   2016   VDRL                                          Psychosis                                                                   0%
  Hajjaj I\[[@pntd.0005880.ref033]\]            Morocco         1   2010   TPHA / VDRL                                   Meningitis                                                                  0%
  Bourazza A\[[@pntd.0005880.ref034]\]          Morocco         5   2008   VDRL                                          Meningovascular                                                             0%
  Hsaini Y\[[@pntd.0005880.ref035]\]            Morocco         3   2010   Syphilis serology not otherwise specified     Tabes Dorsalis                                                              0%

10.1371/journal.pntd.0005880.t002

###### Patients presenting with neurological syndromes---Inclusion criteria, clinical and diagnostic features.

![](pntd.0005880.t002){#pntd.0005880.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                       Country            n                                                               Year   Study Design                    Study Duration   Study Inclusion Criteria                                     CSF Criteria for Diagnosis of Neurosyphilis   Neurosyphilis Syndrome          Prevalence of Neurosyphilis                  \% HIV Positive Patients
  ------------------------------------------- ------------------ --------------------------------------------------------------- ------ ------------------------------- ---------------- ------------------------------------------------------------ --------------------------------------------- ------------------------------- -------------------------------------------- ---------------------------------
  Benabdeljili M\[[@pntd.0005880.ref036]\]    Morocco            563                                                             2016   Retrospective                   13 years         Patients with dementia between 2000--2013                    Not Stated                                    General Paresis of the Insane   3.60%                                        Not Stated

  Amare A\[[@pntd.0005880.ref037]\]           Ethiopia           25 tested for neurosyphilis (total study sample size n = 119)   2008   Retrospective                   10 years         Status Epilepticus in patients aged ≥13                      VDRL                                          Status Epilepticus              8%                                           Not stated

  Siddiqi OK\[[@pntd.0005880.ref038]\]        Zambia             81                                                              2015   Prospective                     23 months        New Seizure in HIV Adults                                    VDRL                                                                          0%[^\#^](#t002fn003){ref-type="table-fn"}    100%

  Chraa M\[[@pntd.0005880.ref039]\]           Morocco            128                                                             2014   Retrospecive                    4 Years          Stroke in adults 18--45                                      Not Stated                                    Meningovascular Syphilis        7.80%                                        Not Stated

  Kumwenda JJ\[[@pntd.0005880.ref040]\]       Malawi             59                                                              2005   Prospective                     8 months         Presentation with Stroke                                     VDRL                                          Meningovascular Syphilis        0%                                           0.48

  Sokrab TE\[[@pntd.0005880.ref041]\]         Sudan              96                                                              2002   Prospetive                      Not Given        Presentation with Stroke                                     VDRL                                          Meningovascular Syphilis        4.20%                                        Not Stated

  de Mast Q\[[@pntd.0005880.ref042]\]         Tanzania           158 cases 369 controls                                          2016   Prosepctive Case Conrol Study   3 Years          Case Control Study: Presentation with Stroke                 No CSF Testing Treponemal IgG in Blood        Meningovascular Syphilis        ^N/A^\                                       24.5% in cases 6.5% in controls

  Silber E---1999\[[@pntd.0005880.ref043]\]   South Africa       60                                                              1999   Prospective                     5 months         Suspected Meningitis                                         RPR / TPHA                                    Meningitis                      3.30%                                        68.00%

  Jarvis J\[[@pntd.0005880.ref044]\]          South Africa       4,961                                                           2010   Retrospective                   3 years          Suspected Meningitis                                         TPHA / VDRL                                   Meningitis                      1.27%[\^](#t002fn001){ref-type="table-fn"}   XX

  Rajasingham R\[[@pntd.0005880.ref045]\]     Uganda             117                                                             2015   Prospective                     2 years          HIV with suspected meningitis                                VDRL                                          Meningitis                      2.70%                                        100%

  Szabo I\[[@pntd.0005880.ref046]\]           Uganda and Kenya   288                                                             2013   Prospecive                      4 Months         Patients presenting with neurology---not further specified   Not Stated                                                                    11.1%[\*](#t002fn002){ref-type="table-fn"}   12.15%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\^ Of the 4,961 individuals undergoing lumbar puncture for suspected meningitis 2,291 were found to have normal CSF and a further 931 patients were found to have changes compatible with HIV alone. 1,737 individuals had an LP compatible with meningitis of whom 22 were diagnosed with neurosyphilis.

\* The diagnosis explaining the patients neurology is stated to be Syphilis in 32 patients in this study but clear CSF diagnostic criteria are not stated

^\#^ 5% of patients were found to have postive syphilis serology but were negative on testing of the CSF

10.1371/journal.pntd.0005880.t003

###### Patients with syphilis investigated for neurosyphilis---Inclusion criteria, clinical and diagnostic features.

![](pntd.0005880.t003){#pntd.0005880.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Country        n     Year   Study Design    Study Duration   Study Inclusion Criteria                                         CSF Criteria for Diagnosis of Neurosyphilis           Neurosyphilis Syndrome                                 Prevalence of Neurosyphilis                \% HIV Positive Patients
  ------------------------------------------ -------------- ----- ------ --------------- ---------------- ---------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------ -----------------------------------------
  Yahyaoui M\[[@pntd.0005880.ref047]\]       Morroco        201   2005   Retrospective   10 years         Clinical diagnosis of Neurosyphilis with positive CSF serology   VDRL or TPHA                                          Dementia n = 145\                                      100%                                       29 Patients tested with prevalence 6.9%
                                                                                                                                                                                                                                 Meningovascular n = 45\                                                                           
                                                                                                                                                                                                                                 Tabes dorsalis n = 20\                                                                            
                                                                                                                                                                                                                                 Ocular Syphilis n = 13\                                                                           
                                                                                                                                                                                                                                 Other n = 21                                                                                      

  Rafai M.A \[[@pntd.0005880.ref048]\]       Morocco        55    2012   Retrospective   12 Years         Clinical diagnosis of Neurosyphilis with positive CSF serology   Syphilis Serology not otherwise specified             General Paresis of the Insane n = 24\                  100%                                       0%
                                                                                                                                                                                                                                 Meningovascular Syphilis n = 20\                                                                  
                                                                                                                                                                                                                                 Tabes Dorsalis n = 9\                                                                             
                                                                                                                                                                                                                                 Other n = 3                                                                                       

  Allali F\[[@pntd.0005880.ref049]\]         Morocco        24    2006   Retrospective   20 years         Arthropathy due to Tabes Dorsalis                                Treponemal Antibodies                                 Tabes Dorsalis                                         33.30%                                     0%

  Timmermans M\[[@pntd.0005880.ref050]\]     South Africa   161   2004   Retrospective   10 years         Positive CSF FTA                                                 CSF FTA                                               Dementia n = 82\                                       100%                                       0%
                                                                                                                                                                                                                                 Stroke n = 24\                                                                                    
                                                                                                                                                                                                                                 Spinal cord disease n = 15\                                                                       
                                                                                                                                                                                                                                 Seizures n = 14                                                                                   

  Molepo J\[[@pntd.0005880.ref051]\]         South Africa   50    2007   Prospective     15 Months        Suspected Neurosyphilis                                          VDRL / FTA                                                                                                   80%[\^](#t003fn001){ref-type="table-fn"}   Not Stated

  Cisse A---2002\[[@pntd.0005880.ref052]\]   Guinea         28    2002   Retrospective   8 Years          Neurosyphilis with focal neurology                               VDRL / TPHA                                           Focal neurology[\*](#t003fn002){ref-type="table-fn"}   100%                                       0%

  Reekie I\[[@pntd.0005880.ref053]\]         South Africa   31    2016   Retrospective   20 months        Patients with clinical Ocular Syphilis                           CSF Pleocytosis / FTA                                 Ocular Syphilis                                        25.80%                                     50% of patients with Neurosyphilis

  Tattevin P\[[@pntd.0005880.ref054]\]       Mozambique     21    2002   Prospective     20 Months        Latent Syphilis in HIV positive patients                         Protein \>50mg/dl WBC \> 5/mm Positive CSF RPR test   Asymptomatic Neurosyphilis                             19%                                        100%

  Nnoruka EN\[[@pntd.0005880.ref055]\]       Nigeria        31    2005   Prospective     8 Months         Patients with HIV & Syphilis seen in Dermatology Clinic          VDRL                                                  Asymptomatic Neurosyphilis                             0%                                         100%

  Modi G\[[@pntd.0005880.ref056]\]           South Africa   506   2007   Prospective     6 Months         All HIV Positive Patients                                        Syphilis Serology not otherwise specified             Asymptomatic Neurosyphilis                             0.20%                                      100%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\^ A further 10% of patients negative by serology were reported to be PCR positive for T.pallidum in CSF

\* The study authors report that as well as these \'atypical cases\' they 11 cases of Tabes dorsalis, 4 cases of syphilis meningitis, 8 cases of meningovascular syphilis and 13 cases of general paresis of the insane

Case reports {#sec011}
------------

Twenty-one case reports including 37 patients were identified \[[@pntd.0005880.ref015]--[@pntd.0005880.ref035]\]. The clinical syndromes included focal neurological manifestations such as cranial nerve involvement and including range of manifestations including meningitis, meningovascular syphilis, tabes dorsalis and dementia ([Table 1](#pntd.0005880.t001){ref-type="table"}).

Patients presenting with a neurological syndrome {#sec012}
------------------------------------------------

Eleven studies reported data on patients presenting with neurological syndromes ([Table 2](#pntd.0005880.t002){ref-type="table"}). The methodological quality of many of these studies was poor ([Table 4](#pntd.0005880.t004){ref-type="table"}). At least one major methodological limitation was identified in half. Six studies were retrospective (54.5%) and only eight (72.7%) included the performance of lumbar punctures to make the diagnosis of neurosyphilis. Several studies did not provide clear diagnostic criteria for neurosyphilis and, even in studies where LP was performed, it was frequently not performed on all patients enrolled in the study.

10.1371/journal.pntd.0005880.t004

###### Methodological assessment of criteria used for diagnosis of neurosyphilis.

![](pntd.0005880.t004){#pntd.0005880.t004g}

  Study                                       Study Methodology               Criteria for diagnosis of Neurosyphilis                                                 
  ------------------------------------------- ------------------------------- ----------------------------------------- ---------------------- ---------------------- ---------------------
  Benabdeljili M\[[@pntd.0005880.ref036]\]    Retrospective                   Yes                                       Yes                    Yes                    Not Clearly Defined
  Amare A\[[@pntd.0005880.ref037]\]           Retrospective                   Not Stated                                No                     No                     Clearly Defined
  Siddiqi OK\[[@pntd.0005880.ref038]\]        Prospective                     Yes                                       Yes                    Yes                    Clearly Defined
  Chraa M\[[@pntd.0005880.ref039]\]           Retrospective                   No                                        Testing Not Peformed   Testing Not Peformed   Not Performed
  Kumwenda JJ\[[@pntd.0005880.ref040]\]       Prospective                     Yes                                       No                     Yes                    Clearly Defined
  Sokrab TE\[[@pntd.0005880.ref041]\]         Prospective                     Not Stated                                Not Stated             Not Stated             Clearly Defined
  de Mast Q\[[@pntd.0005880.ref042]\]         Prosepctive Case Conrol Study   No                                        Testing Not Peformed   Testing Not Peformed   Not Performed
  Silber E---1999\[[@pntd.0005880.ref043]\]   Prospective                     Yes                                       Yes                    Yes                    Clearly Defined
  Jarvis J\[[@pntd.0005880.ref044]\]          Retrospective                   Yes                                       Yes                    No                     Clearly Defined
  Rajasingham R\[[@pntd.0005880.ref045]\]     Prospective                     Yes                                       Yes                    Yes                    Clearly Defined
  Szabo I\[[@pntd.0005880.ref046]\]           Prospecive                      Not stated                                No                     Not stated             Not Clearly Defined
  Yahyaoui M\[[@pntd.0005880.ref047]\]        Retrospective                   Yes                                       Yes                    Yes                    Clearly Defined
  Rafai M.A \[[@pntd.0005880.ref048]\]        Retrospective                   Yes                                       Yes                    Yes                    Not Clearly Defined
  Allali F\[[@pntd.0005880.ref049]\]          Retrospective                   Yes                                       Yes                    Yes                    Not Clearly Defined
  Timmermans M\[[@pntd.0005880.ref050]\]      Retrospective                   Yes                                       Yes                    Yes                    Clearly Defined
  Molepo J\[[@pntd.0005880.ref051]\]          Prospective                     Yes                                       Yes                    Yes                    Clearly Defined
  Cisse A---2002\[[@pntd.0005880.ref052]\]    Retrospective                   Yes                                       Yes                    Yes                    Clearly Defined
  Reekie I\[[@pntd.0005880.ref053]\]          Retrospective                   Yes                                       No                     No                     Clearly Defined
  Tattevin P\[[@pntd.0005880.ref054]\]        Prospective                     Yes                                       Yes                    Yes                    Clearly Defined
  Nnoruka EN\[[@pntd.0005880.ref055]\]        Prospective                     Not Stated                                Not Stated             Not Stated             Clearly Defined
  Modi G\[[@pntd.0005880.ref056]\]            Prospective                     Yes                                       Not Stated             Not Stated             Not Clearly Defined

### Dementia {#sec013}

In a single-centre retrospective study from Morocco of 563 patients attending a dementia clinic between 2000--2013 neurosyphilis was reported to be the most common infectious cause of dementia identified, and accounted for 3.6% of all cases of dementia seen during the study period\[[@pntd.0005880.ref036]\]. Details on CSF diagnostics were not provided, so the proportion of these cases which were definitive neurosyphilis is not known.

### Seizures {#sec014}

A retrospective study in Ethiopia of individuals aged over 13 presenting with status epilepticus enrolled a total of 119 patients but only 25 (21%) patients underwent CSF testing for neurosyphilis\[[@pntd.0005880.ref037]\]. In this subgroup a diagnosis of neurosyphilis was made in 2 patients on the basis of a positive CSF VDRL (8%).

In a prospective study in Zambia\[[@pntd.0005880.ref038]\], HIV infected patients with a new onset of seizures were enrolled and underwent CSF testing within two weeks of the index seizure. Three patients had a reactive serum RPR and TPHA, but no individual had a positive CSF VDRL.

### Stroke {#sec015}

In a retrospective study from Morocco of adults aged 18--45 (n = 128) presenting with stroke the underlying diagnosis was reported to be meningovascular syphilis in 14 patients (11%). However CSF diagnostics were not undertaken and syphilis was diagnosed on the basis of serum serological testing, so the proportion of these cases which were definitive neurosyphilis is unknown. \[[@pntd.0005880.ref039]\].

Two prospective studies conducted in Malawi and Sudan enrolled patients presenting with stroke (n = 98 and n = 96 respectively)\[[@pntd.0005880.ref040],[@pntd.0005880.ref041]\]. Lumbar punctures were performed and a positive CSF VDRL was considered diagnostic in both studies. In the study in Malawi \[[@pntd.0005880.ref040]\] 48% of patients were HIV positive. Fifty nine individuals had serum syphilis serology performed. Thirteen patients had a positive TPPA and a negative VDRL and a further five patients had both a positive TPPA and a VDRL. CSF VDRL testing was negative in all patients with positive serological tests on blood. In the study in Sudan both serological and CSF evidence of syphilis were assessed and a positive CSF-VDRL was considered diagnostic of neurosyphilis \[[@pntd.0005880.ref041]\]. The prevalence of HIV was not stated for patients enrolled in the study. Syphilis was identified as the major risk factor for stroke in four patients (4.2%) but no details were given as to whether this was based on serum testing alone or on CSF testing.

A case-control study of stroke conducted in Tanzania between 2003--2006 enrolled 158 stroke cases and 369 age- and sex- matched controls\[[@pntd.0005880.ref042]\]. Serology for syphilis was performed using an IgG ELISA (*Treponema pallidum* IgG ELISA; IBL international GmbH, Hamburg, Germany). The seroprevalence was significantly higher in stroke cases (24.7%) compared to controls (12.7%) and a positive ELISA was associated with a significantly increased risk of stroke (OR 2.8, 95% CI 1.6--4.6). No CSF testing was performed in this study so it is not clear whether this association represents causation and, if so, whether the mechanism is meningovascular syphilis.

### Meningitis {#sec016}

Prospective and retrospective studies in South Africa, and a further prospective study in Uganda, enrolled patients with clinically suspected meningitis. In the prospective South African study, sixty consecutive patients with clinically suspected meningitis were enrolled\[[@pntd.0005880.ref043]\]. The overall seroprevalence for HIV was 68%. Of the 60 enrolled patients a microbiological diagnosis was made in 39 (65%). Meningococcal meningitis accounted for ten cases. Tuberculous meningitis and cryptococcal meningitis each accounted for nine cases. On the basis of a positive CSF RPR and TPHA two cases of neurosyphilis were diagnosed (3.3%)--one with an oculomotor nerve palsy and one with cryptococcal co-infection.

In the retrospective study from South Africa\[[@pntd.0005880.ref044]\], 4,961 episodes of suspected meningitis were included. Neurosyphilis was diagnosed on the basis of a reactive CSF TPHA or VDRL. Of the total population studied, 2,293 were found to have normal CSF and a further 931 patients were found to have changes compatible with HIV alone. Of the 1,737 individuals who had an LP compatible with meningitis a microbiological diagnosis was made in 820 patients (47%). A diagnosis of neurosyphilis was made in 22 patients (1.26% of patients with an abnormal CSF, 3% of patients with a microbiological diagnosis). Testing for neurosyphilis was performed at the physician's discretion and this is likely to be an underestimate of the true proportion of cases caused by neurosyphilis.

In Uganda samples were obtained from patients enrolled in a study ART initiation in HIV positive patients with cryptococcal meningitis \[[@pntd.0005880.ref045]\]. A total of 63 patients negative for Cryptococcus in CSF and 54 patients with Cryptococcal meningitis were assessed. The overall syphilis seroprevalence in these patients was not stated but neurosyphilis was diagnosed in 3 of 111 (2.7%) patients who were tested on the basis of a positive CSF VDRL, accounting for a comparable number of cases as bacterial meningitis (*Streptococcus pneumoniae* n = 4, *Neisseria meningitidis* n = 1).

### Other {#sec017}

In a study conducted at a single site in Uganda and a single site in Kenya, a total of 288 consecutive patients with neurological symptoms were enrolled\[[@pntd.0005880.ref046]\]. All patients underwent a neurological examination but detailed information was not provided on the clinical abnormalities seen. The overall prevalence of HIV was 12.2%. A total of 87 patients underwent CSF testing. Neurosyphilis was the diagnosis in 32 (11.1%) although the proportion of patients who had a diagnosis based on a positive CSF test was not reported, nor was the overall prevalence of syphilis in the study population given.

Studies on neurosyphilis amongst patients with syphilis {#sec018}
-------------------------------------------------------

Ten studies reported on cases of neurosyphilis amongst patients known to have syphilis ([Table 3](#pntd.0005880.t003){ref-type="table"}). The methodological quality of many studies was poor with at least one significant methodological weakness in all but one study ([Table 4](#pntd.0005880.t004){ref-type="table"}). The study design was retrospective for six of the studies (60%) whilst lumbar puncture was performed in only seven studies (70%) for the diagnosis of neurosyphilis but, of these, only five studies (50%) stated what assay was used.

### Suspected neurosyphilis {#sec019}

Two retrospective studies from Morocco reported on a total of 256 patients clinically suspected to have neurosyphilis \[[@pntd.0005880.ref047],[@pntd.0005880.ref048]\]. In the larger study (n = 201), neurosyphilis was diagnosed based on a positive CSF VDRL and TPHA. In the smaller study (n = 55) the authors report patients had a positive CSF serological test for neurosyphilis but do not provide details on which tests were performed. Dementia was the most commonly clinical syndrome seen in 56.6% patients (n = 145) followed by meningovascular syphilis (n = 65, 25.4%) and tabes dorsalis (n = 29, 11.3%).

A further retrospective study from Morocco included 24 patients with arthropathy suspected to be due to tabes dorsalis. CSF testing was performed using a test for treponemal antibodies but the precise test was not stated. In this study all patients had positive syphilis serology on serum while 33.3% of patients had positive CSF serology \[[@pntd.0005880.ref049]\].

A retrospective study from South Africa included patients with neurosyphilis diagnosed on the basis of a positive CSF FTA-ABS seen in a single hospital in the Western Cape region over a ten-year period. A total of 161 patients were identified. Dementia was the most common diagnosis (n = 81, 50.9%), followed by meningovascular syphilis (n = 24, 14.9%)\[[@pntd.0005880.ref050]\].

In a prospective study in South Africa\[[@pntd.0005880.ref051]\], 50 patients with suspected neurosyphilis were enrolled. All patients were seropositive for syphilis and clinically diagnosed with tertiary neurosyphilis although detailed clinical information was not provided. All underwent lumbar puncture. Forty patients (80%) had reactive CSF serology (70% VDRL and FTA-ABS, 10% FTA-ABS alone) and a further 5 patients (10%) had a positive CSF PCR but negative CSF serology.

Finally, a case-series from a single centre in Guinea reported 28 patients who were diagnosed with neurosyphilis on the basis of both a positive CSF VDRL and CSF-TPHA \[[@pntd.0005880.ref052]\]. The series included a broad spectrum of neurological presentations including three cases of facial nerve palsy, four cases of optic atrophy, eleven cases of seizures, three cases of cerebellar ataxia, two cases of vestibular-cochlear nerve dysfunction and five cases of clinical meningitis.

### Ocular syphilis {#sec020}

A retrospective study from South Africa included patients clinically diagnosed with ocular syphilis (n = 68), all of whom had positive serum serology results. Four cases were known to be HIV positive, one HIV negative, and the status was unknown for the remaining three cases. Thirty-one (45.6%) patients underwent lumbar puncture (not all of whom had CSF serologica testing) and, of these, a quarter (n = 8) had CSF findings felt to be consistent with neurosyphilis \[[@pntd.0005880.ref053]\]. In five cases this was a reactive CSF FTA-ABS and, in three cases, this was a CSF lymphocyic pleocytosis.

### Individuals with HIV and syphilis co-infection {#sec021}

Three studies were identified reporting on the prevalence of neurosyphilis in individuals with HIV. In a study assessing treatment of HIV co-infected individuals in Mozambique\[[@pntd.0005880.ref054]\], twenty-one patients with latent syphilis underwent lumbar puncture at baseline. Four patients (19%) were diagnosed with asymptomatic neurosyphilis. None had a positive CSF RPR, all had elevated CSF protein and two had a CSF pleocytosis (WBC \> 5/mm^3^). As all patients were co-infected with HIV the significance of a pleocystosis greater than 5/mm^3^ is uncertain. All patients were re-examined at 3, 6 and 12 months. At six months follow-up one patient still had an abnormal CSF (elevated protein and pleocyosis) but no patients had an abnormal CSF by twelve months.

In a study conducted between 2000 and 2001, 31 patients with syphilis and HIV co-infection were seen at a dermatology clinic in Nigeria. All had early syphilis (primary syphilis = 9, secondary syphilis = 20 and latent syphilis = 2). The authors report that no cases of neurosyphilis were seen, but details are not provided on what proportion of patients underwent CSF examination\[[@pntd.0005880.ref055]\].

Finally, in a study of 506 consecutive HIV infected patients in Johannesburg only one case of neurosyphilis was identified \[[@pntd.0005880.ref056]\], but neither the prevalence of syphilis nor the number of patients who underwent lumbar puncture is given, so the interpretation of this finding is extremely limited.

Diagnostic criteria {#sec022}
-------------------

CSF diagnostic criteria varied across studies ([Table 4](#pntd.0005880.t004){ref-type="table"}). The most commonly used criteria were CSF VDRL alone (n = 14 studies) followed by CSF VDRL combined with either a CSF TPHA (n = 9 studies) or FTA-ABS (n = 2 studies). Two studies defined neurosyphilis as reactive CSF FTA-ABS with or without pleocytosis and two studies used the RPR and TPHA assays on CSF. One study defined neurosyphilis as any one of an abnormal CSF protein, white cell count or CSF RPR assay. Ten studies stated that CSF was tested using serological assays but did not clearly state which diagnostic test was used.

Discussion {#sec023}
==========

This is the first systematic review of the literature on neurosyphilis in Africa. The methodological quality of the majority of the studies was poor and as such limited conclusions can be drawn. The available data are clearly inadequate data to robustly estimate the prevalence of neurosyphilis in Africa or the proportion of cases of important neurological syndromes due to neurosyphilis. The data are also inadequate to address any potential interaction between HIV and syphilis in this setting.

Whilst HIV has been reported in Africa since the 1980s we restricted our search to papers published after 1990. By this point the HIV epidemic was fully established and any impact of HIV on the risk of neurosyphilis might be anticipated o have become apparent. Whilst we used comprehensive search and MESH terms to identify papers it is possible that some studies on oto-syphilis or other forms of neurosyphilis, or studies which did not explicitly mention Africa (or an African country) might have been missed. Despite these limitations, we believe our comprehensive search strategy is likely to have identified nearly all the relevant research papers for this systematic review.

A major methodological failing of many studies was an inadequate approach to diagnostic criteria for neurosyphilis. A number of studies included only serum testing without CSF examination, whilst others did not adequately report the specific CSF assay performed. In part, this may reflect the lack of an adequate gold-standard. There is a clear need to better define standards for use in routine diagnosis in low-resource settings, but also for use in research studies.

The studies on patients presenting with stroke are all limited by methodological weaknesses. Across these studies there appears to be a consistent association between positive serum syphilis serology and stroke but, as only a minority of studies undertook CSF examination, these studies are difficult to interpret, and whether this reflects neurosyphilis is uncertain. It is possible that the association truly reflects meningovascular syphilis, emboli due to cardiovascular syphilis, or confounding factors. Further studies are needed to better delineate the role of syphilis as a cause of stroke in Africa.

Studies from Morocco continue to report late-stage neurosyphilis, but the majority of studies are of low methodological quality. In comparison there appear to be few cases of tertiary neurosyphilis reported from sub-Saharan Africa. Given the weaknesses of most of the studies it is extremely uncertain whether this represents a true difference in the frequency of tertiary neurosyphilis or simply reflects reporting/publication bias or lack of access to medical resources for diagnosis. It has been hypothesised that the ease of access to short courses of penicillin in the community may have altered the natural history of syphilis, resulting in a lower frequency of late stage manifestations, but this would not explain why cases continue to be seen in North Africa but not sub-Saharan Africa.

There was a small number of higher quality prospective studies enrolling patients with suspected meningitis, in which neurosyphilis was identified \[[@pntd.0005880.ref043],[@pntd.0005880.ref045]\]. These studies had clear inclusion criteria, included adequate data on denominators, and clear diagnostic criteria for neurosyphilis. In these studies the prevalence of neurosyphilis was approximately 3%. In these studies the frequency of neurosyphilis was similar to that of *S*.*pneumoniae* as a cause of meningitis, which likely reflects that patients predominantly had subacute meningitis. This would make syphilis an important and treatable cause of meningitis in Africa. Given the limitations of CSF serological assays, it is likely that the true proportion of meningitis due to neurosyphilis is higher.

The clinical epidemiology of neurosyphilis in Africa remains poorly understood and the majority of studies included in this review were of low methodological quality. Inadequate diagnostics remain a major barrier to progress in our understanding of these important diseases. Future well-designed prospective studies are needed to better delineate the incidence and clinical spectrum of neurosyphilis in Africa.
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